24150-38-7

Upstream product

• 2635-13-4 1,2-(methylenedioxy)-4-bromobenzene 
• 78647-56-0 t-2,c-3-bishydroxymethyl-6,7-dimethoxy-r-1-(3,4-methylenedioxyphenyl)-1,2,3,4-tetrahydronaphthalene 
• 77-78-1 dimethyl sulfate 
• 10240-16-1 (6S,7R,8R)-8-Benzo[1,3]dioxol-5-yl-3-methoxy-6,7-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-ol 
• 120-57-0 piperonal 
• 72430-92-3 4-[(3,4-dimethoxyphenyl)methyl]dihydrofuran-2-one 
• 115061-18-2 (E)-3-(methoxycarbonyl)-4-(3,4-dimethoxyphe-nyl)but-3-enoic acid 
• 78647-52-6 (+/-)-4-(3,4-dimethoxyphenyl)-3-methoxycarbonylbutanoic acid 
• 78647-55-9 3-hydroxymethyl-6,7-dimethoxy-1-(3',4'-methylenedioxyphenyl)-1,2,3,4-tetrahydro-2-naphthoic acid γ-lactone 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 77516-07-5 (1S,2R,3S)-1-Benzo[1,3]dioxol-5-yl-6,7-dimethoxy-3-methyl-4-oxo-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid dimethylamide 
• 77516-07-5 (1S,2R,3R)-1-Benzo[1,3]dioxol-5-yl-6,7-dimethoxy-3-methyl-4-oxo-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid dimethylamide 
• 77516-08-6 (1S,2S,3R)-1-Benzo[1,3]dioxol-5-yl-6,7-dimethoxy-3-methyl-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid dimethylamide 
• 77516-09-7 (5S,6S,7R)-5-Benzo[1,3]dioxol-5-yl-6-hydroxymethyl-3-methoxy-7-methyl-5,6,7,8-tetrahydro-naphthalen-2-ol 

Relevant academic research and scientific papers

ABSOLUTE CONFIGURATION OF THE LIGNAN OLEIFERINS FROM VIROLA OLEIFERA

The assignment of the absolute configuration for the lignan-7-ols, (7R,8S,8'R)-olieferins A-C, was established by acid catalysed Friedel-Crafts-type cyclization for the known 2,7'-cyclolignans and chemical analyses.

Design, synthesis and biological evaluation of substituted (+)-SG-1 derivatives as novel anti-HIV agents

SG-1 was previously identified as a potent Non-nucleoside reverse transcriptase inhibitors (NNRTI) which works through inhibition of reverse transcriptase (RT) RNA-dependent DNA polymerase activity via a direct binding event. To further investigate the relationship between its structure and activity, four series of novel analogues were designed and synthesized with 12 of them inhibiting HIV-1 replication with IC50s in the range 0.09–6.71 μM. Compound 4b, 4c, 4f, 2 and 6b were further tested on two NNRTI-resistant HIV-1 strains and one NNRTI-resistant superbug. The result showed that RT- E138K/M184V mutant virus conferred 4.7–9.1-fold resistance to 4c, 4f, 2 and 6b, but only showed slight resistance to 4b (2-fold) which was better than SG-1.

Synthesis of Aryltetralin and Dibenzylbutyrolactone Lignans: (+/-)-Lintetralin, (+/-)-Phyltetralin, and (+/-)-Kusunokinin

Application of a general synthetic pathway for aryltetralin and dibenzylbutyrolactone lignans, starting from the lithium enolate of 3-(3,4-dimethoxybenzyl)butyrolactone (1) led to syntheses of (+/-)-lintetralin (4), (+/-)-phyltetralin (5), (+/-)-isogalcat

TANDEM CONJUGATE ADDITION-α-ALKYLATION OF UNSATURATED AMIDES. SYNTHESIS OF 1-ARYLTETRALIN LIGNANS

The amide alcohols 5,6, obtained in one step from the sequential reaction of N,N-dimethylcrotonamide with dithiane 3 anion and aryl aldehyde 4, were efficiently converted into the lignans galcatin (2a) and isogalcatin (2b).